Your biomarkers

Your results, matched to the options that depend on them.

Most of what narrows a treatment list comes down to a handful of test results. Enter the ones you have and this will show which documented options each finding relates to, and which tests would open more. No records, no uploads, nothing leaves your device.

Before you start

Enter only the biomarker results below. Do not enter your name, date of birth, record number, or any other detail that identifies you, and do not upload reports or medical records.

What you select is saved on this device, and there is no account. We do not sell it or share it with anyone, and your results are never attached to your name. You can clear everything at any time.

From the pathology report

Read off the biopsy or surgical report.

Muscle invasion

Whether the tumour has grown into the muscle layer of the bladder wall, read off the resection pathology.

Histology

Whether the tumour is pure urothelial carcinoma or contains variant subtypes, which can change how aggressively it is treated.

Protein staining on tissue

Usually reported at diagnosis.

PD-L1 expression

How much PD-L1 the tumour and surrounding immune cells express.

HER2 expression

HER2 protein level on the tumour. Strong expression can open a HER2-directed antibody-drug conjugate across tumour types.

Tumour sequencing

From comprehensive genomic profiling.

FGFR2 / FGFR3 alterationneeds sequencing

Mutations or fusions in the FGFR genes. One of the most actionable findings in urothelial cancer.

Mismatch repair / MSIneeds sequencing

Whether the tumour has lost mismatch-repair function, reported as MSI-high or dMMR.

Tumour mutational burdenneeds sequencing

How many mutations the tumour carries. Bladder cancers are often relatively high.

NTRK gene fusionneeds sequencing

An uncommon fusion that is targetable across tumour types when present.

DNA-repair gene alterationsneeds sequencing

Alterations in repair genes such as ERCC2, ATM, RB1 or FANCC, studied as markers of chemotherapy sensitivity.

Blood-based testing

From a liquid biopsy.

Circulating tumour DNA

Tumour DNA detected in blood, used to look for disease remaining after treatment.

This panel covers the findings that most often change which documented options apply. Two of the largest decisions in this disease, whether cisplatin can be given safely and whether the bladder can be preserved, rest on overall health and tumour features rather than on a biomarker, and are covered in the Treatments section.